Interrupting ErbB receptor transactivation by a combined inhibitor of ADAM10 and ADAM17 reduced non-small-lung-cancer-cell formation, subcutaneous tumor growth, and breast cancer and fibroplasia [259, 260]. This evidence concerns the gene ADAM10 and breast cancer.